The primary aim of the trial is to determine whether adjunctive treatment with tirzepatide over 32 weeks reduces body weight in patients with T1D who are overweight or obese, compared to those receiving insulin‐only therapy. This evidence concerns the gene INS and type 1 diabetes mellitus.